Inhaled drugs as risk factors for communityacquired pneumonia

J. Almirall; I. Bolíbar; M. Serra-Prat; E. Palomera; J. Roig; I. Hospital; E. Carandelle; M. Agustí; P. Ayuso; A. Estela; A. Torres; J. M. De Salas; J. Costa; M. Tristany; M. J. Grau; S. Sancho; E. Miguel; M. Fradera; I. Ochoa; M. J. Castany; A. Quilez; V. Marina; P. Subias; B. Jimeno; null Bradnovich; M. Rodriguez; E. Ramon; A. Gardella; C. Ginés; J. C. Montero; P. Flores; P. Serra; E. Torrellas; C. Serrano; M. Pubill; J. Gost; I. Buxadé; J. Mussoll; X. Mestres; A. Armada; J. Mallafré; M. Roger; M. T. Gros; N. Les; J. Joanola; J. Doménech; M. Bundó; M. Trilla; J. Massons; J. Montero; E. Zurilla; M. Alegre; M. Papiol; O. Martí; M. Catalá; M. A. Martinez; A. Casanovas; I. Beisani; C. Tria; E. Diaz; P. Torán; M. M. Aizpurua; G. Lozano; J. Casals; J. Sorribes; D. Torrellas; A. Casas; J. Bernad; A. De Montoliu; J. Gaya; R. Vallés; A. Vazquez; R. Peiró; G. Aresté; G. N. Mengual; M. C. Viñes; E. Almerich; M. A. Lopez; J. Bel; A. Gosalves; S. Macip; E. Carrillo; P. Paulo; M. Pol; J. Sala; P. Mir; J. L.L. Anglada; J. Salabarnada; E. Sanz; F. Gorgas; A. Ribas; E. Fau; I. Pellicer; S. Morales; E. Burdoy; M. Bartolomé; E. Corona; L. Mateu; M. Paret; Y. Verde

doi:10.1183/09031936.00022909

Inhaled drugs as risk factors for communityacquired pneumonia

J. Almirall, I. Bolíbar, M. Serra-Prat, E. Palomera, J. Roig, I. Hospital, E. Carandelle, M. Agustí, P. Ayuso, A. Estela, A. Torres, J. M. De Salas, J. Costa, M. Tristany, M. J. Grau, S. Sancho, E. Miguel, M. Fradera, I. Ochoa, M. J. CastanyA. Quilez, V. Marina, P. Subias, B. Jimeno, Bradnovich, M. Rodriguez, E. Ramon, A. Gardella, C. Ginés, J. C. Montero, P. Flores, P. Serra, E. Torrellas, C. Serrano, M. Pubill, J. Gost, I. Buxadé, J. Mussoll, X. Mestres, A. Armada, J. Mallafré, M. Roger, M. T. Gros, N. Les, J. Joanola, J. Doménech, M. Bundó, M. Trilla, J. Massons, J. Montero, E. Zurilla, M. Alegre, M. Papiol, O. Martí, M. Catalá, M. A. Martinez, A. Casanovas, I. Beisani, C. Tria, E. Diaz, P. Torán, M. M. Aizpurua, G. Lozano, J. Casals, J. Sorribes, D. Torrellas, A. Casas, J. Bernad, A. De Montoliu, J. Gaya, R. Vallés, A. Vazquez, R. Peiró, G. Aresté, G. N. Mengual, M. C. Viñes, E. Almerich, M. A. Lopez, J. Bel, A. Gosalves, S. Macip, E. Carrillo, P. Paulo, M. Pol, J. Sala, P. Mir, J. L.L. Anglada, J. Salabarnada, E. Sanz, F. Gorgas, A. Ribas, E. Fau, I. Pellicer, S. Morales, E. Burdoy, M. Bartolomé, E. Corona, L. Mateu, M. Paret, Y. Verde

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

33 Cites (Scopus)

Resum

The effect of inhaled drugs in community-acquired pneumonia (CAP) is unclear. This case-control study was designed to determine whether inhaled drugs were risk factors for CAP. All incident cases of confirmed CAP that occurred over 1 yr in patients with chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD) or asthma were included, as well as CB, COPD and asthma controls. Risk factors for CAP and inhaled treatment were recorded during a personal interview. An effect of inhaled drugs on the risk of CAP was observed in COPD and asthma patients after adjusting for the effect of other respiratory diseases and their concomitant treatments. In COPD patients, inhaled steroids had a risk OR of 3.26 (95% CI 1.07-9.98) and in asthma patients inhaled anticholinergics had a risk OR of 8.80 (95% CI 1.02-75.7). In CB patients, no association with CAP was observed for any inhaler. These effects were independent of adjusting variables related to severity and other respiratory and non-respiratory risk factors for CAP, including vaccines. Inhaled β2-adrenergic agonists did not show a significant effect on the risk of CAP in any of the respiratory diseases. Inhaled steroids may favour CAP in COPD patients, whereas anticholinergics may favour CAP in asthma patients. It is difficult to differentiate the effect of inhaled therapy from the effect of COPD or asthma severity on the risk of CAP, and these relationships may not be causal, but could call attention to inhaled therapy in COPD and asthma patients. Copyright©ERS 2010.

Idioma original	Anglès
Pàgines (de-a)	1080-1087
Revista	European Respiratory Journal
Volum	36
Número	5
DOIs	https://doi.org/10.1183/09031936.00022909
Estat de la publicació	Publicada - 1 de nov. 2010

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1183/09031936.00022909

Com citar-ho

Almirall, J., Bolíbar, I., Serra-Prat, M., Palomera, E., Roig, J., Hospital, I., Carandelle, E., Agustí, M., Ayuso, P., Estela, A., Torres, A., De Salas, J. M., Costa, J., Tristany, M., Grau, M. J., Sancho, S., Miguel, E., Fradera, M., Ochoa, I., ... Verde, Y. (2010). Inhaled drugs as risk factors for communityacquired pneumonia. European Respiratory Journal, 36(5), 1080-1087. https://doi.org/10.1183/09031936.00022909

@article{b7f919c00beb4c7f8fa44dc284b7f04b,

title = "Inhaled drugs as risk factors for communityacquired pneumonia",

abstract = "The effect of inhaled drugs in community-acquired pneumonia (CAP) is unclear. This case-control study was designed to determine whether inhaled drugs were risk factors for CAP. All incident cases of confirmed CAP that occurred over 1 yr in patients with chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD) or asthma were included, as well as CB, COPD and asthma controls. Risk factors for CAP and inhaled treatment were recorded during a personal interview. An effect of inhaled drugs on the risk of CAP was observed in COPD and asthma patients after adjusting for the effect of other respiratory diseases and their concomitant treatments. In COPD patients, inhaled steroids had a risk OR of 3.26 (95% CI 1.07-9.98) and in asthma patients inhaled anticholinergics had a risk OR of 8.80 (95% CI 1.02-75.7). In CB patients, no association with CAP was observed for any inhaler. These effects were independent of adjusting variables related to severity and other respiratory and non-respiratory risk factors for CAP, including vaccines. Inhaled β2-adrenergic agonists did not show a significant effect on the risk of CAP in any of the respiratory diseases. Inhaled steroids may favour CAP in COPD patients, whereas anticholinergics may favour CAP in asthma patients. It is difficult to differentiate the effect of inhaled therapy from the effect of COPD or asthma severity on the risk of CAP, and these relationships may not be causal, but could call attention to inhaled therapy in COPD and asthma patients. Copyright{\textcopyright}ERS 2010.",

keywords = "Community-acquired pneumonia, Inhaled drug treatment, Risk factors",

author = "J. Almirall and I. Bol{\'i}bar and M. Serra-Prat and E. Palomera and J. Roig and I. Hospital and E. Carandelle and M. Agust{\'i} and P. Ayuso and A. Estela and A. Torres and {De Salas}, {J. M.} and J. Costa and M. Tristany and Grau, {M. J.} and S. Sancho and E. Miguel and M. Fradera and I. Ochoa and Castany, {M. J.} and A. Quilez and V. Marina and P. Subias and B. Jimeno and Bradnovich and M. Rodriguez and E. Ramon and A. Gardella and C. Gin{\'e}s and Montero, {J. C.} and P. Flores and P. Serra and E. Torrellas and C. Serrano and M. Pubill and J. Gost and I. Buxad{\'e} and J. Mussoll and X. Mestres and A. Armada and J. Mallafr{\'e} and M. Roger and Gros, {M. T.} and N. Les and J. Joanola and J. Dom{\'e}nech and M. Bund{\'o} and M. Trilla and J. Massons and J. Montero and E. Zurilla and M. Alegre and M. Papiol and O. Mart{\'i} and M. Catal{\'a} and Martinez, {M. A.} and A. Casanovas and I. Beisani and C. Tria and E. Diaz and P. Tor{\'a}n and Aizpurua, {M. M.} and G. Lozano and J. Casals and J. Sorribes and D. Torrellas and A. Casas and J. Bernad and {De Montoliu}, A. and J. Gaya and R. Vall{\'e}s and A. Vazquez and R. Peir{\'o} and G. Arest{\'e} and Mengual, {G. N.} and Vi{\~n}es, {M. C.} and E. Almerich and Lopez, {M. A.} and J. Bel and A. Gosalves and S. Macip and E. Carrillo and P. Paulo and M. Pol and J. Sala and P. Mir and Anglada, {J. L.L.} and J. Salabarnada and E. Sanz and F. Gorgas and A. Ribas and E. Fau and I. Pellicer and S. Morales and E. Burdoy and M. Bartolom{\'e} and E. Corona and L. Mateu and M. Paret and Y. Verde",

year = "2010",

month = nov,

day = "1",

doi = "10.1183/09031936.00022909",

language = "English",

volume = "36",

pages = "1080--1087",

number = "5",

}

Almirall, J, Bolíbar, I, Serra-Prat, M, Palomera, E, Roig, J, Hospital, I, Carandelle, E, Agustí, M, Ayuso, P, Estela, A, Torres, A, De Salas, JM, Costa, J, Tristany, M, Grau, MJ, Sancho, S, Miguel, E, Fradera, M, Ochoa, I, Castany, MJ, Quilez, A, Marina, V, Subias, P, Jimeno, B, Bradnovich, Rodriguez, M, Ramon, E, Gardella, A, Ginés, C, Montero, JC, Flores, P, Serra, P, Torrellas, E, Serrano, C, Pubill, M, Gost, J, Buxadé, I, Mussoll, J, Mestres, X, Armada, A, Mallafré, J, Roger, M, Gros, MT, Les, N, Joanola, J, Doménech, J, Bundó, M, Trilla, M, Massons, J, Montero, J, Zurilla, E, Alegre, M, Papiol, M, Martí, O, Catalá, M, Martinez, MA, Casanovas, A, Beisani, I, Tria, C, Diaz, E, Torán, P, Aizpurua, MM, Lozano, G, Casals, J, Sorribes, J, Torrellas, D, Casas, A, Bernad, J, De Montoliu, A, Gaya, J, Vallés, R, Vazquez, A, Peiró, R, Aresté, G, Mengual, GN, Viñes, MC, Almerich, E, Lopez, MA, Bel, J, Gosalves, A, Macip, S, Carrillo, E, Paulo, P, Pol, M, Sala, J, Mir, P, Anglada, JLL, Salabarnada, J, Sanz, E, Gorgas, F, Ribas, A, Fau, E, Pellicer, I, Morales, S, Burdoy, E, Bartolomé, M, Corona, E, Mateu, L, Paret, M & Verde, Y 2010, 'Inhaled drugs as risk factors for communityacquired pneumonia', European Respiratory Journal, vol. 36, núm. 5, pàg. 1080-1087. https://doi.org/10.1183/09031936.00022909

TY - JOUR

T1 - Inhaled drugs as risk factors for communityacquired pneumonia

AU - Almirall, J.

AU - Bolíbar, I.

AU - Serra-Prat, M.

AU - Palomera, E.

AU - Roig, J.

AU - Hospital, I.

AU - Carandelle, E.

AU - Agustí, M.

AU - Ayuso, P.

AU - Estela, A.

AU - Torres, A.

AU - De Salas, J. M.

AU - Costa, J.

AU - Tristany, M.

AU - Grau, M. J.

AU - Sancho, S.

AU - Miguel, E.

AU - Fradera, M.

AU - Ochoa, I.

AU - Castany, M. J.

AU - Quilez, A.

AU - Marina, V.

AU - Subias, P.

AU - Jimeno, B.

AU - Bradnovich, null

AU - Rodriguez, M.

AU - Ramon, E.

AU - Gardella, A.

AU - Ginés, C.

AU - Montero, J. C.

AU - Flores, P.

AU - Serra, P.

AU - Torrellas, E.

AU - Serrano, C.

AU - Pubill, M.

AU - Gost, J.

AU - Buxadé, I.

AU - Mussoll, J.

AU - Mestres, X.

AU - Armada, A.

AU - Mallafré, J.

AU - Roger, M.

AU - Gros, M. T.

AU - Les, N.

AU - Joanola, J.

AU - Doménech, J.

AU - Bundó, M.

AU - Trilla, M.

AU - Massons, J.

AU - Montero, J.

AU - Zurilla, E.

AU - Alegre, M.

AU - Papiol, M.

AU - Martí, O.

AU - Catalá, M.

AU - Martinez, M. A.

AU - Casanovas, A.

AU - Beisani, I.

AU - Tria, C.

AU - Diaz, E.

AU - Torán, P.

AU - Aizpurua, M. M.

AU - Lozano, G.

AU - Casals, J.

AU - Sorribes, J.

AU - Torrellas, D.

AU - Casas, A.

AU - Bernad, J.

AU - De Montoliu, A.

AU - Gaya, J.

AU - Vallés, R.

AU - Vazquez, A.

AU - Peiró, R.

AU - Aresté, G.

AU - Mengual, G. N.

AU - Viñes, M. C.

AU - Almerich, E.

AU - Lopez, M. A.

AU - Bel, J.

AU - Gosalves, A.

AU - Macip, S.

AU - Carrillo, E.

AU - Paulo, P.

AU - Pol, M.

AU - Sala, J.

AU - Mir, P.

AU - Anglada, J. L.L.

AU - Salabarnada, J.

AU - Sanz, E.

AU - Gorgas, F.

AU - Ribas, A.

AU - Fau, E.

AU - Pellicer, I.

AU - Morales, S.

AU - Burdoy, E.

AU - Bartolomé, M.

AU - Corona, E.

AU - Mateu, L.

AU - Paret, M.

AU - Verde, Y.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The effect of inhaled drugs in community-acquired pneumonia (CAP) is unclear. This case-control study was designed to determine whether inhaled drugs were risk factors for CAP. All incident cases of confirmed CAP that occurred over 1 yr in patients with chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD) or asthma were included, as well as CB, COPD and asthma controls. Risk factors for CAP and inhaled treatment were recorded during a personal interview. An effect of inhaled drugs on the risk of CAP was observed in COPD and asthma patients after adjusting for the effect of other respiratory diseases and their concomitant treatments. In COPD patients, inhaled steroids had a risk OR of 3.26 (95% CI 1.07-9.98) and in asthma patients inhaled anticholinergics had a risk OR of 8.80 (95% CI 1.02-75.7). In CB patients, no association with CAP was observed for any inhaler. These effects were independent of adjusting variables related to severity and other respiratory and non-respiratory risk factors for CAP, including vaccines. Inhaled β2-adrenergic agonists did not show a significant effect on the risk of CAP in any of the respiratory diseases. Inhaled steroids may favour CAP in COPD patients, whereas anticholinergics may favour CAP in asthma patients. It is difficult to differentiate the effect of inhaled therapy from the effect of COPD or asthma severity on the risk of CAP, and these relationships may not be causal, but could call attention to inhaled therapy in COPD and asthma patients. Copyright©ERS 2010.

AB - The effect of inhaled drugs in community-acquired pneumonia (CAP) is unclear. This case-control study was designed to determine whether inhaled drugs were risk factors for CAP. All incident cases of confirmed CAP that occurred over 1 yr in patients with chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD) or asthma were included, as well as CB, COPD and asthma controls. Risk factors for CAP and inhaled treatment were recorded during a personal interview. An effect of inhaled drugs on the risk of CAP was observed in COPD and asthma patients after adjusting for the effect of other respiratory diseases and their concomitant treatments. In COPD patients, inhaled steroids had a risk OR of 3.26 (95% CI 1.07-9.98) and in asthma patients inhaled anticholinergics had a risk OR of 8.80 (95% CI 1.02-75.7). In CB patients, no association with CAP was observed for any inhaler. These effects were independent of adjusting variables related to severity and other respiratory and non-respiratory risk factors for CAP, including vaccines. Inhaled β2-adrenergic agonists did not show a significant effect on the risk of CAP in any of the respiratory diseases. Inhaled steroids may favour CAP in COPD patients, whereas anticholinergics may favour CAP in asthma patients. It is difficult to differentiate the effect of inhaled therapy from the effect of COPD or asthma severity on the risk of CAP, and these relationships may not be causal, but could call attention to inhaled therapy in COPD and asthma patients. Copyright©ERS 2010.

KW - Community-acquired pneumonia

KW - Inhaled drug treatment

KW - Risk factors

U2 - 10.1183/09031936.00022909

DO - 10.1183/09031936.00022909

M3 - Article

SN - 0903-1936

VL - 36

SP - 1080

EP - 1087

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 5

ER -

Inhaled drugs as risk factors for communityacquired pneumonia

Resum

SDG de les Nacions Unides

Accés al document

Fingerprint

Com citar-ho